CD38 and neoplasm: Second, the tumor’s genomic risk features (1q gain; extensive CNA burden) and driver spectrum overlapping MM raise concern for occult or future systemic disease, favoring a proteasome inhibitor–IMiD–anti-CD38 backbone with demonstrated activity in extramedullary settings.